IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.675
EU - Europa 1.709
AS - Asia 1.215
SA - Sud America 48
AF - Africa 9
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.660
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.635
SE - Svezia 721
SG - Singapore 543
CN - Cina 503
GB - Regno Unito 177
IT - Italia 151
FR - Francia 137
BE - Belgio 108
RU - Federazione Russa 88
DE - Germania 83
IN - India 69
FI - Finlandia 43
BR - Brasile 40
UA - Ucraina 40
CZ - Repubblica Ceca 37
VN - Vietnam 35
CA - Canada 31
IR - Iran 14
AT - Austria 13
IE - Irlanda 13
BG - Bulgaria 10
NL - Olanda 10
ES - Italia 9
JP - Giappone 8
PL - Polonia 8
HK - Hong Kong 7
HR - Croazia 7
RS - Serbia 6
TR - Turchia 6
IL - Israele 5
NO - Norvegia 5
PT - Portogallo 5
RO - Romania 5
AL - Albania 4
DK - Danimarca 4
HU - Ungheria 4
LT - Lituania 4
AR - Argentina 3
AU - Australia 3
CH - Svizzera 3
MT - Malta 3
NG - Nigeria 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BD - Bangladesh 2
CR - Costa Rica 2
EE - Estonia 2
EG - Egitto 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MX - Messico 2
PH - Filippine 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
A1 - Anonimo 1
BO - Bolivia 1
BS - Bahamas 1
BT - Bhutan 1
CL - Cile 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
GL - Groenlandia 1
GR - Grecia 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MC - Monaco 1
ME - Montenegro 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PY - Paraguay 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
Totale 15.660
Salva come PNG Salva come JPEG
Città #
Fairfield 2.052
Chandler 1.765
Ashburn 1.170
Woodbridge 1.033
Cambridge 906
Seattle 906
Houston 815
Wilmington 649
Nyköping 566
Ann Arbor 395
Singapore 384
Lawrence 244
Roxbury 230
Des Moines 145
Beijing 141
Brussels 106
Paris 104
San Diego 97
Inglewood 91
Dearborn 88
New York 86
Jacksonville 78
Brooklyn 62
Los Angeles 59
Pune 54
London 52
Bari 51
Boardman 50
Santa Clara 45
Nanjing 40
Washington 34
Brno 26
Edinburgh 26
San Mateo 26
Falls Church 23
Helsinki 23
Dong Ket 22
Princeton 22
Ruvo Di Puglia 20
Jinan 19
Munich 19
Norwalk 17
Hefei 16
Monmouth Junction 16
Shanghai 15
Augusta 14
Guangzhou 14
Dublin 13
Grafing 13
Jiaxing 13
Marseille 13
Vienna 12
Leawood 11
Prescot 11
Zhengzhou 11
Chicago 10
Nanchang 10
Shenyang 10
Sofia 10
Toronto 10
Ardabil 9
Hanoi 9
Kilburn 9
Frankfurt am Main 8
Kunming 8
Olomouc 8
Ottawa 8
Amsterdam 7
Dallas 7
Hebei 7
Madrid 7
Stockholm 7
Tokyo 7
Warsaw 7
Zagreb 7
Atlanta 6
Belgrade 6
Changsha 6
Chiswick 6
Hounslow 6
Miami 6
Montreal 6
Ningbo 6
Rome 6
San Francisco 6
Tianjin 6
Cinisello Balsamo 5
Milan 5
Mumbai 5
New Bedfont 5
Oslo 5
Redwood City 5
Shenzhen 5
Wuhan 5
Budapest 4
Fuzhou 4
Longyan 4
Mottola 4
San Jose 4
Southwark 4
Totale 13.208
Salva come PNG Salva come JPEG
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 188
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 135
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 132
Angiogenesis in adenosquamous cancer of pancreas 126
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 121
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 118
Targeting angiogenesis in biliary tract cancers: An open option 114
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 113
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 109
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 109
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 106
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 105
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 103
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 103
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 102
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 101
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 96
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 96
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 96
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 95
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 95
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 95
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 95
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 95
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 95
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 94
Challenges and opportunities of MicroRNAs in lymphomas 94
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 93
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 92
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 92
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 92
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 91
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 91
Immunotherapeutic approaches for hepatocellular carcinoma 90
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 90
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 90
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 89
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 87
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 87
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 87
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 86
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 85
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. 85
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 85
Bone metastases in biliary cancers: A multicenter retrospective survey 85
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 84
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 84
Torch study: How much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? 83
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 82
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 82
Antineoplastic drug-induced bradyarrhythmias 82
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 82
null 81
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 81
Synthetic lethality to overcome cancer drug resistance 81
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 81
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 81
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 81
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 80
null 80
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 80
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 80
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 80
Unique case of giant adult paratesticular spindle cell rhabdomyosarcoma 79
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 79
p53 as the main traffic controller of the cell signaling network 79
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 78
The process of truth disclosure: An assessment of the results of information during the diagnostic phase in patients with cancer 78
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 78
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 77
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 77
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 77
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 77
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 77
Combined modality treatments in pancreatic cancer 76
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 76
Oncosuppressor methylation: A possible key role in colon metastatic progression 76
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 76
Current status of targeted therapies in advanced gastric cancer 75
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 75
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 75
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 75
Adjuvant therapy in colon cancer 75
Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report 74
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico dell'Italia meridionale multicenter phase II study 74
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 74
Target therapies in pancreatic carcinoma 74
The Italian Rare Pancreatic Exocrine Cancer Initiative 73
Synchronous Mandibular and Giant Parieto-occipital Skull Metastasis From Hepatocellular Carcinoma 73
Update on capecitabine alone and in combination regimens in colorectal cancer patients 73
Role of gemcitabine in metastatic breast cancer patients: A short review 73
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 73
Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report 72
null 72
Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM) 72
Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN) 72
Molecular classifications of gastric cancers: Novel insights and possible future applications 72
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 72
Takotsubo syndrome in a patient treated with sunitinib for renal cancer 71
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 71
Totale 8.763
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.141
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.141
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.173 0 0 0 0 0 448 470 711 798 283 333 130
2020/20213.144 229 178 417 362 287 330 206 252 217 283 265 118
2021/20222.204 157 210 40 77 159 150 111 133 142 112 225 688
2022/20233.694 402 514 291 362 319 412 111 475 538 26 205 39
2023/20241.176 83 217 81 104 125 324 19 66 9 28 10 110
2024/20251.285 96 83 362 208 155 381 0 0 0 0 0 0
Totale 16.242